

Canadian Patent Issued for Cynata Therapeutics Unique Stem Cell Technology

Melbourne, Australia; 3 March 2020: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP or “the Company”), announced today that the Canadian Intellectual Property Office (CIPO) has granted a patent covering Cynata’s proprietary Cymerus™ mesenchymal stem cell technology. The patent application, entitled “Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum free conditions”, is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

This patent extends Cynata’s robust intellectual property protection of its Cymerus platform which provides a unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, who are founders, advisors and shareholders of Cynata.

The patent has an expiration date of 16 March 2031.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, sepsis, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.